Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban.
Luis Ortega-PazFrancesco FranchiFabiana RolliniMattia GalliLatonya BeenGhussan GhanemAwss ShalhoubTiffany OssiAndrea RivasXuan ZhouAndres M Pineda MaldonadoSiva SuryadevaraDaniel SofferMartin M ZenniLisa K JenningsDominick J AngiolilloPublished in: Thrombosis and haemostasis (2023)
In patients with CCS, switching from different DAPT regimens to DPI was feasible, showing enhanced P2Y12 inhibition with DAPT and reduced TG with DPI, with no differences in platelet-mediated global thrombogenicity between DPI and ticagrelor- and prasugrel, but not clopidogrel-, based DAPT.